Compare TALK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | DBVT |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.1M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | TALK | DBVT |
|---|---|---|
| Price | $3.52 | $22.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $4.83 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 1.2M | 723.1K |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $214,593,000.00 | $5,502,000.00 |
| Revenue This Year | $23.86 | $1,768.71 |
| Revenue Next Year | $22.22 | $1,028.88 |
| P/E Ratio | $140.51 | ★ N/A |
| Revenue Growth | ★ 18.37 | N/A |
| 52 Week Low | $2.22 | $2.74 |
| 52 Week High | $4.36 | $26.19 |
| Indicator | TALK | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 73.91 |
| Support Level | $3.43 | $20.27 |
| Resistance Level | $3.67 | $26.19 |
| Average True Range (ATR) | 0.14 | 1.73 |
| MACD | 0.03 | 0.74 |
| Stochastic Oscillator | 78.69 | 74.17 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.